Patrys has developed two humanised forms of deoxymab 3E10, called PAT-DX1 and PAT-DX3, which have improved activity over the original 3E10 antibody, and which have been further optimised for efficacy and manufacturability.
Partnerships
Patrys has a number of research collaborations in place including a major program with the Yale University. Patrys has an active program to establish new commercial and research partnerships in order to leverage the full potential of its deoxymab technology for the development of revolutionary, new therapeutic products.
Current Deoxymab Portfolio
PAT-DX3 full sized antibody
PAT-DX3 is a humanised, full-sized antibody, that has been further optimised to improve its therapeutic potential. PAT-DX3 is likely to have clinical utility for treating primary and secondary brain cancers due to its ability to cross the blood brain barrier. It may also have utility for treating cancers and/or metastases that are associated with NETosis, or in combination with DNA damaging agents such as radiation and many chemotherapy drugs.
PAT-DX3 is expected to have different pharmaceutic properties (tissue distribution, pharmacokinetic profile etc) to PAT-DX1 due to its larger size. Patrys believes these will open up further opportunities to leverage its deoxymab platform and to develop additional therapeutic products.
PAT-DX1 antibody fragment
PAT-DX1 is a dimer of a small antibody fragment derived from a humanised version of the binding domain from the original mouse deoxymab antibody 3E10. Patrys has manufactured a large scale GMP batch of PAT-DX1 and is seeking strategic partnerships for co-development and licensing of PAT-DX1.
